Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis

HAEMATOLOGICA

FERRATA STORTI FOUNDATION

1. National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award (CCITLA)
2. NCI of the National Institutes of Health [P30 CA016359]
3. Celgene
4. Acceleron
5. Abbvie
6. Otsuka
7. Pfizer
8. Medimmune/AstraZeneca
9. Boehringer-Ingelheim
10. Trovagene
11. Incyte
12. Takeda
13. ADC Therapeutics
14. Cellerant
15. Orsenix
16. Biosight